CTLA4 and neoplasm: Key strategies include immune checkpoint inhibitors, which block inhibitory receptors like programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4, and adoptive cell therapies, which involve the transfer of tumor-specific T cells or NK cells into patients.